Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 162 | 3 | 195 | +36 |
| Shares | 43.4M | 366.7K | 40.3M | −2.76M (−6.4%) |
| Value | $1.43B | $12.1M | $2.23B | +$814.3M (+57.6%) |
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (58)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (22)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Cowen and Company, LLC | 2,197,385 | $72.3M |
| ExodusPoint Capital Management, LP | 883,043 | $29.0M |
| Healthcare of Ontario Pension Plan Trust Fund | 338,400 | $11.1M |
| TCG Crossover Management, LLC | 231,820 | $7.62M |
| Vestal Point Capital, LP | 230,000 | $7.56M |
| Clearbridge Investments, LLC | 191,374 | $6.29M |
| Emerald Advisers, LLC | 146,298 | $4.81M |
| Emerald Mutual Fund Advisers Trust | 109,692 | $3.61M |
| Jump Financial, LLC | 74,957 | $2.47M |
| Connor, Clark & Lunn Investment Management Ltd. | 47,060 | $1.55M |
| Brevan Howard Capital Management LP | 43,380 | $1.43M |
| ADAR1 Capital Management, LLC | 25,900 | $851.9K |
| Verition Fund Management LLC | 23,199 | $763.0K |
| Gsa Capital Partners LLP | 22,493 | $740.0K |
| Nebula Research & Development LLC | 17,684 | $581.6K |
| Ieq Capital, LLC | 12,640 | $415.7K |
| Golden State Equity Partners | 900 | $29.6K |
| nVerses Capital, LLC | 700 | $23.0K |
| Quest Partners LLC | 504 | $16.6K |
| Private Trust Co NA | 79 | $2.60K |
| Global Retirement Partners, LLC | 38 | $1.25K |
| Capital Performance Advisors LLP | 5 | $164 |
Not filed for Q4 2024 yet (3)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Ghost Tree Capital, LLC | 350,000 | $11.5M |
| Raymond James Financial Services Advisors, Inc. | 10,362 | $340.8K |
| AJOVista, LLC | 6,305 | $207.4K |